ICI may lead to durable responses as well as complete responses for patients with recurrent or metastatic cSCC, but only roughly 50% of patients will achieve a response to treatment; for those who do not respond to this therapy, other systemic options include cytotoxic chemotherapy or EGFR inhibition. This evidence concerns the gene EGFR and skin squamous cell carcinoma.